Passage Bio
PASG
54 hedge funds and large institutions have $31.4M invested in Passage Bio in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 12 closing their positions.
0.2% less ownership
Funds ownership: 3.25% → 3.05% (-0.2%)
7% less funds holding
Funds holding: 58 → 54 (-4)
8% less capital invested
Capital invested by funds: $34M → $31.4M (-$2.64M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
Top Buyers
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.7M |
| 2 |
O
OrbiMed
New York
|
+$1.18M |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$593K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$414K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$97.6K |
Top Sellers
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$2.22M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.89M |
| 3 |
NM
Newtyn Management
New York
|
-$637K |
| 4 |
JP Morgan Chase
New York
|
-$581K |
| 5 |
Morgan Stanley
New York
|
-$158K |
PASG Hedge Fund Activity: Q2 2023 in Review
54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2023, worth a combined $31.4M — down 7.8% from $34M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PASG and 8 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 9 added.
The largest buyer was BML Capital Management, adding an estimated $1.7M. The largest seller was Lynx1 Capital Management, cutting an estimated $2.22M.
- 54 institutional investors held Passage Bio (PASG) as of Q2 2023, down from 58 in Q1 2023.
- Funds reported $31.4M of Passage Bio stock for Q2 2023, down 7.8% quarter-over-quarter.
- 8 funds opened new Passage Bio positions in Q2 2023 and 12 closed out, a net change of -4 holders.
- The largest Passage Bio buyer in Q2 2023 was BML Capital Management, an estimated $1.7M added.
- The largest Passage Bio seller in Q2 2023 was Lynx1 Capital Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2023.